Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Alzamend Neuro Inc ALZN

Healthcare Biotechnology
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.


NDAQ:ALZN - Post by User

Alzamend Neuro Inc
<< Previous
 Bullboard Posts
User Avatar Image
(200)
•••
Post by whytestockson Oct 15, 2024 12:16pm
11 Views
Post# 36266500

Alzamend Neuro Regains Compliance with Nasdaq Listing Standa

Alzamend Neuro Regains Compliance with Nasdaq Listing Standa
NEWS: $ALZN Alzamend Neuro Regains Compliance with Nasdaq Listing StandardsAlzamend Neuro, Inc. (Nasdaq: ALZN) (&#x201C; Alzamend &#x201D;), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer&#x2019;s disease (&#x201C; Alzheimer&#x2019;s &#x201D;), bipolar disorder (&#x201C; BD &#x201D;), major de...ALZN - Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities